- Home
- PYN vs PMN Comparison
PYN vs PMN Comparison
Compare PYN & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- PMN
- Stock Information
- Founded
- PYN 2002
- PMN 2004
- Country
- PYN United States
- PMN Canada
- Employees
- PYN N/A
- PMN N/A
- Industry
- PYN Investment Managers
- PMN Pharmaceuticals and Biotechnology
- Sector
- PYN Finance
- PMN Health Care
- Exchange
- PYN Nasdaq
- PMN Nasdaq
- Market Cap
- PYN 34.5M
- PMN 29.8M
- IPO Year
- PYN N/A
- PMN N/A
- Fundamental
- Price
- PYN $5.84
- PMN $0.96
- Analyst Decision
- PYN
- PMN
- Analyst Count
- PYN 0
- PMN 0
- Target Price
- PYN N/A
- PMN N/A
- AVG Volume (30 Days)
- PYN 19.9K
- PMN 43.3K
- Earning Date
- PYN 01-01-0001
- PMN 03-31-2025
- Dividend Yield
- PYN 5.07%
- PMN N/A
- EPS Growth
- PYN N/A
- PMN N/A
- EPS
- PYN N/A
- PMN N/A
- Revenue
- PYN N/A
- PMN N/A
- Revenue This Year
- PYN N/A
- PMN N/A
- Revenue Next Year
- PYN N/A
- PMN N/A
- P/E Ratio
- PYN N/A
- PMN N/A
- Revenue Growth
- PYN N/A
- PMN N/A
- 52 Week Low
- PYN $4.84
- PMN $0.87
- 52 Week High
- PYN $6.60
- PMN $2.61
- Technical
- Relative Strength Index (RSI)
- PYN 60.65
- PMN 56.16
- Support Level
- PYN $5.68
- PMN $0.90
- Resistance Level
- PYN $5.77
- PMN $0.95
- Average True Range (ATR)
- PYN 0.04
- PMN 0.06
- MACD
- PYN 0.02
- PMN 0.01
- Stochastic Oscillator
- PYN 89.47
- PMN 67.79
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.